Key Performance Indicators
Integ. Proteins is currently trading at Rs 141.55 on the BSE under ticker INTPROT, carrying a market capitalisation of Rs 264.89 crore. The price-to-earnings ratio stands at 1151.69 times. The six-month price return is +311.48%. The most recently reported quarterly net profit Rs 0.19 crore, representing a year-on-year change of -9.52%. Quarterly sales stand at Rs 5.69 crore, with a year-on-year change of -73.52%. The return on capital employed (ROCE) is 1.26%. The all-time high price is Rs 155.00, above the current market price.
Highlights
Integ. Proteins has delivered a six-month price return of 311.48%, placing it among the notable performers on the BSE over the measured period. The all-time high of Rs 155.00 is above the current price of Rs 141.55, indicating the stock has corrected from its historical peak by approximately 8.7%. The market capitalisation of Rs 264.89 crore at this price level reflects the cumulative re-rating the market has applied to the company's equity.
The price-to-earnings ratio of 1151.69 times is extremely elevated — among the highest in this collection — indicating the current market capitalisation is priced at a substantial premium to current earnings and implying very high growth expectations from the current earnings base. India's consumption economy is growing with rising incomes, formalisation of retail, and brand premiumisation across food, personal care, and household goods.
Business Overview
Integrated Proteins is a food processing company in the protein ingredients or food manufacturing segment. Protein processing companies manufacture high-protein food ingredients — soy protein, whey, casein, or functional food proteins — for the food industry, animal nutrition sector, and health supplement market. India's growing awareness of protein nutrition, the rapid expansion of health and wellness food products, and rising demand for animal feed as the livestock sector formalises create multiple demand drivers for protein ingredient manufacturers.
The P/E of 1,151.69 times on a quarterly profit of Rs 0.19 crore indicates a company where even thin positive earnings generate an extreme P/E at the current market cap of Rs 264.89 crore. The quarterly profit decline of -9.52% and revenue decline of -73.52% are concerning near-term trends that contrast with the six-month return of 311.48%. The all-time high of Rs 155.00 is above the current price of Rs 141.55 — a 9% correction. Investors should examine the cause of the sharp revenue decline through the company's quarterly results commentary.
Financial Analysis
The financial profile of Integ. Proteins requires careful contextualisation. The six-month return of 311.48% has generated a market capitalisation of Rs 264.89 crore which must be assessed against the current operational scale: quarterly revenue of Rs 5.69 crore and quarterly net profit of Rs 0.19 crore. The P/E of 1151.69 times is one of the defining valuation characteristics of this stock — at this extreme multiple, even maintaining the current earnings level would require an exceptionally long period of compounding before the P/E normalises to market-average levels without further earnings growth.
The return on capital employed of 1.26% is marginally positive, indicating the business is beginning to generate positive returns on deployed capital — an improvement from a negative ROCE position. The quarterly revenue decline of -73.52% year-on-year is a near-term concern that investors should investigate through the company's quarterly results commentary.
At Rs 264.89 crore market capitalisation, Integ. Proteins has small-cap status. Investors should ensure they access and analyse the company's most recent quarterly results, annual report, and any corporate announcements on BSE before committing capital based solely on observed price performance.
Investor Highlights
The investment case for Integ. Proteins at the current price is determined by the gap between the current market capitalisation of Rs 264.89 crore and the company's intrinsic business value — a calculation that depends on assumptions about future revenue growth, margin improvement, and competitive positioning. The six-month return of 311.48% identifies this as a stock that the market has chosen to dramatically revalue upward, with the analytical question being whether the current valuation level is justified by the fundamental business trajectory.
With the current price of Rs 141.55 approximately 8.7% below the all-time high of Rs 155.00, the stock has experienced a correction from its historical peak. The key assessment is whether this correction represents a value opportunity — if the fundamental business case remains intact — or an ongoing normalisation following a period of speculative overextension.
The positive quarterly profitability of Rs 0.19 crore provides a fundamental anchor that distinguishes Integ. Proteins from the pre-revenue or loss-making entities in this collection. A profitable business — even at thin absolute levels — provides the basis for P/E-based valuation, dividend capacity assessment, and earnings trend analysis that loss-making businesses cannot.
Frequently Asked Questions
Q: What does Integ. Proteins do and what sector does it operate in?
A: Integ. Proteins operates in the consumer sector, listed on the BSE under the ticker INTPROT. The company's specific products, services, revenue model, and customer base are documented in its annual report and exchange filings available through the BSE corporate filing portal at bseindia.com.
Q: What does the six-month return of 311.48% reflect for Integ. Proteins?
A: The six-month return of 311.48% reflects significant positive market re-rating of the company's equity from its price six months prior. This re-rating may be driven by company-specific developments — new contracts, business expansion, or improved financial performance — or by broader sector-level positive sentiment. Investors should verify the specific triggers through the company's BSE exchange disclosures and quarterly results.
Q: What does the P/E ratio of 1151.69 times imply for Integ. Proteins?
A: The P/E of 1151.69 times means investors are paying Rs 1152 for every rupee of trailing annual earnings. At this extreme level, the market is pricing in very substantial future earnings growth — implying the current profit base will multiply many times over the investment horizon for the current price to be justified on a normalised earnings basis.
Q: What is Integ. Proteins's current market capitalisation and all-time high?
A: Integ. Proteins has a market capitalisation of Rs 264.89 crore at the current price of Rs 141.55. The all-time high is Rs 155.00, which is above the current price, indicating the stock has corrected from its historical peak.
Q: Where can investors find Integ. Proteins's official financial data and corporate disclosures?
A: All of Integ. Proteins's financial disclosures — quarterly results, annual reports, shareholding patterns, board announcements, and corporate actions — are filed with the BSE and are freely accessible at bseindia.com through the company's filing page. SEBI's listing obligations mandate timely disclosure of all material developments. These filings are the primary source of verified financial and operational information for investment assessment.
SEO Meta
Meta Title: Integ. Proteins Stock Analysis 2025: 311.48% Six-Month Return, KPI Breakdown, and Business Overview
Meta Description: Integ. Proteins (BSE: INTPROT) has delivered a 311.48% six-month return with a market cap of Rs 264.89 crore and P/E of 1151.69x. This analysis covers key performance indicators, business overview, financial analysis, and investor highlights.
Keywords: Integ. Proteins share price 2025, INTPROT stock, Integ. Proteins BSE, Integ. Proteins all-time high, Integ. Proteins consumer sector, India small-cap stocks 2025, Integ. Proteins market cap, Integ. Proteins six-month return, Integ. Proteins P/E ratio